{"id":2848,"date":"2025-02-08T13:17:23","date_gmt":"2025-02-08T10:17:23","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2848"},"modified":"2025-02-08T13:17:24","modified_gmt":"2025-02-08T10:17:24","slug":"sarcomatrix-to-present-its-latest-advancements-in-the-development-of-its-lead-drug-candidate-s-969","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/zh\/sarcomatrix-to-present-its-latest-advancements-in-the-development-of-its-lead-drug-candidate-s-969\/","title":{"rendered":"Sarcomatrix \u5c06\u5c55\u793a\u5176\u4e3b\u8981\u5019\u9009\u836f\u7269 S-969 \u5f00\u53d1\u7684\u6700\u65b0\u8fdb\u5c55"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Sarcomatrix Therapeutics, a clinical-stage biotechnology company focused on revolutionizing treatments for muscle-related diseases, today announced its participation at the 2025 BIO CEO &amp; Investor Conference. The event, set for February 10-11, 2025, at the New York Marriott Marquis, will serve as a platform for Sarcomatrix to showcase its latest advancements in the development of its lead drug candidate, S-969. [Read More: <a href=\"https:\/\/bcic.bio.org\/2025-program\/sarcomatrix-therapeutics-corp\" target=\"_blank\" rel=\"noreferrer noopener\">BIO CEO &amp; Investor Conference<\/a>]<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">David Craig, CEO of Sarcomatrix, will deliver a presentation detailing the company\u2019s significant progress in preclinical development and its strategic roadmap toward initiating Phase 1 clinical trials in 2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">What is DMD Drug Candidate S-969?<\/h2>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/02\/Sarcomatrix-Therapeutics-2-1024x576.jpg\" alt=\"Sarcomatrix Therapeutics Lead Drug Candidate S-969. What is DMD Drug Candidate S-969?\" class=\"wp-image-2851\" title=\"\" srcset=\"https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/02\/Sarcomatrix-Therapeutics-2-1024x576.jpg 1024w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/02\/Sarcomatrix-Therapeutics-2-300x169.jpg 300w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/02\/Sarcomatrix-Therapeutics-2-768x432.jpg 768w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/02\/Sarcomatrix-Therapeutics-2-1536x864.jpg 1536w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/02\/Sarcomatrix-Therapeutics-2-18x10.jpg 18w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/02\/Sarcomatrix-Therapeutics-2-747x420.jpg 747w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/02\/Sarcomatrix-Therapeutics-2-150x84.jpg 150w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/02\/Sarcomatrix-Therapeutics-2-696x392.jpg 696w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/02\/Sarcomatrix-Therapeutics-2-1068x601.jpg 1068w, https:\/\/dmdwarrior.com\/wp-content\/uploads\/2025\/02\/Sarcomatrix-Therapeutics-2.jpg 1920w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">S-969, a first-in-class small molecule targeting a key kinase on the Hippo-YAP axis, has demonstrated promising potential in addressing debilitating conditions such as Duchenne muscular dystrophy (DMD), sarcopenia, and other degenerative muscle disorders.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cThis is a transformative moment for Sarcomatrix as we prepare to transition S-969 into clinical development,\u201d said David Craig. \u201cOur robust preclinical data, coupled with a clear regulatory strategy and growing investor confidence, positions 2025 as a landmark year for our company and the patients we aim to serve.\u201d<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Learn More:<\/strong> <a href=\"https:\/\/dmdwarrior.com\/new-gene-therapies-for-duchenne-muscular-dystrophy\/\">Potential Upcoming New Gene Therapies for Duchenne Muscular Dystrophy<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sarcomatrix Therapeutics, a clinical-stage biotechnology company focused on revolutionizing treatments for muscle-related diseases, today announced its participation at the 2025 BIO CEO &amp; Investor Conference. The event, set for February 10-11, 2025, at the New York Marriott Marquis, will serve as a platform for Sarcomatrix to showcase its latest advancements in the development of its [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2850,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[250,66,249,247,248],"class_list":["post-2848","post","type-post","status-publish","format-standard","has-post-thumbnail","category-research","tag-david-craig","tag-duchenne-muscular-dystrophy","tag-s-969","tag-sarcomatrix","tag-sarcomatrix-therapeutics"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts\/2848","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/comments?post=2848"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/posts\/2848\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/media\/2850"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/media?parent=2848"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/categories?post=2848"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/zh\/wp-json\/wp\/v2\/tags?post=2848"}],"curies":[{"name":"\u53ef\u6e7f\u6027\u7c89\u5242","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}